GLUE insider filings
Monte Rosa Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-06. Screen GLUE transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 3 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings by 3 insiders — 13,864 shares, $322,086 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: sale of 9,500 shares @ $23.18 ($220,219) by Warmuth Markus, filed 2026-07-17.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Warmuth Markus — President & CEO, Director | 1 | — | 1 leg · 9,500 sh · $220,219 | — |
| Champoux Jennifer — Chief Operating Officer | 1 | — | 1 leg · 4,351 sh · $101,730 | 2 |
| Bowen Matthew — Principal Accounting Officer | 1 | — | 1 leg · 13 sh · $137 | — |
Recent insider filings — Monte Rosa Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-06 | 4 | Bowen Matthew — Principal Accounting Officer | Sale (S): 13 @ $10.56 | EDGAR |
| 2026-07-17 | 4 | Warmuth Markus — President & CEO, Director | Sale (S): 9,500 @ $23.18 | EDGAR |
| 2026-07-16 | 4 | Champoux Jennifer — Chief Operating Officer | Option exercise (M): 4,351 @ $3.98 · Sale (S): 4,351 @ $23.38 · Option exercise (M): 4,351 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Townson Sharon — Chief Scientific Officer | Option exercise (M): 6,000 @ $6.14 · Sale (S): 5,600 @ $23.25 · Sale (S): 400 @ $24.13 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Behbahani Ali — Director | Other (J): 1,000,000 @ $0 · Other (J): 15,000 @ $0 · Other (J): 15,000 @ $0 | EDGAR |
| 2026-07-01 | 4 | Janku Filip — Chief Medical Officer | Option exercise (M): 5,407 @ $13.41 · Sale (S): 5,407 @ $24.50 · Option exercise (M): 5,407 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Janku Filip — Chief Medical Officer | Option exercise (M): 6,000 @ $7.56 · Sale (S): 6,000 @ $22.95 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Manning Anthony M. — Director | Option exercise (M): 10,000 @ $4.16 · Sale (S): 10,000 @ $23.11 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Janku Filip — Chief Medical Officer | Option exercise (M): 6,000 @ $7.56 · Sale (S): 11,845 @ $20.22 · Option exercise (M): 30,000 @ $7.56 · Sale (S): 30,000 @ $21.42 · Option exercise (M): 6,000 (derivative) @ $0 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Townson Sharon — Chief Scientific Officer | Option exercise (M): 3,000 @ $6.14 · Sale (S): 3,000 @ $20 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Champoux Jennifer — Chief Operating Officer | Option exercise (M): 2,175 @ $3.98 · Sale (S): 2,175 @ $20 · Option exercise (M): 2,175 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Champoux Jennifer — Chief Operating Officer | Option exercise (M): 2,176 @ $3.98 · Sale (S): 2,176 @ $19 · Option exercise (M): 2,176 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Townson Sharon — Chief Scientific Officer | Option exercise (M): 3,000 @ $6.14 · Sale (S): 3,000 @ $19 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Skvarka Jan — Director | Grant/award (A): 25,800 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Hughes Eric A — Director | Grant/award (A): 25,800 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Blackwell Kimberly — Director | Grant/award (A): 25,800 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Siu Christine — Director | Grant/award (A): 25,800 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Manning Anthony M. — Director | Grant/award (A): 25,800 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Behbahani Ali — Director | Grant/award (A): 25,800 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | SCHIFF ANDREW N — Director | Grant/award (A): 25,800 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Warmuth Markus — President & CEO, Director | Sale (S): 4,998 @ $19.41 · Sale (S): 468 @ $19.73 | EDGAR |
| 2026-06-01 | 4 | Townson Sharon — Chief Scientific Officer | Option exercise (M): 6,000 @ $6.14 · Sale (S): 6,000 @ $19.87 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Champoux Jennifer — Chief Operating Officer | Option exercise (M): 2,175 @ $3.98 · Sale (S): 2,175 @ $20 · Option exercise (M): 2,175 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Champoux Jennifer — Chief Operating Officer | Option exercise (M): 2,176 @ $3.98 · Sale (S): 2,176 @ $19 · Option exercise (M): 2,176 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Manning Anthony M. — Director | Option exercise (M): 10,000 @ $4.16 · Sale (S): 10,000 @ $18.01 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Warmuth Markus — President & CEO, Director | Sale (S): 5,467 @ $18.92 | EDGAR |
| 2026-04-15 | 4 | Warmuth Markus — President & CEO, Director | Sale (S): 8,000 @ $17.64 | EDGAR |
| 2026-04-10 | 4 | Nickson Philip — Chief Business & Legal Officer | Sale (S): 5,845 @ $17.69 | EDGAR |
| 2026-04-07 | 4 | Bowen Matthew — Principal Accounting Officer | Grant/award (A): 4,300 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Dunn Edmund — Principal Accounting Officer | Sale (S): 139 @ $17.96 | EDGAR |
| 2026-03-04 | 4 | Warmuth Markus — President & CEO, Director | Sale (S): 5,466 @ $17.92 | EDGAR |
| 2026-03-02 | 4 | Dunn Edmund — Principal Accounting Officer | Option exercise (M): 25,164 @ $13.41 · Sale (S): 25,164 @ $18.10 · Option exercise (M): 536 @ $13.41 · Sale (S): 536 @ $17.50 · Option exercise (M): 25,164 (derivative) @ $0 · Option exercise (M): 536 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Janku Filip — Chief Medical Officer | Sale (S): 9,189 @ $19.50 | EDGAR |
| 2026-01-09 | 4 | Warmuth Markus — President & CEO, Director | Sale (S): 3,707 @ $23.24 · Sale (S): 1,450 @ $23.88 · Sale (S): 309 @ $24.57 | EDGAR |
| 2026-01-05 | 4 | Nickson Philip — Chief Business & Legal Officer | Grant/award (A): 28,000 · Sale (S): 3,155 @ $15.17 · Grant/award (A): 126,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Champoux Jennifer — Chief Operating Officer | Grant/award (A): 35,000 · Sale (S): 2,629 @ $15.17 · Grant/award (A): 158,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Dunn Edmund — Principal Accounting Officer | Sale (S): 1,039 @ $15.17 | EDGAR |
| 2026-01-05 | 4 | Warmuth Markus — President & CEO, Director | Grant/award (A): 90,000 · Sale (S): 10,135 @ $15.17 · Grant/award (A): 406,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Janku Filip — Chief Medical Officer | Grant/award (A): 31,000 · Sale (S): 3,155 @ $15.17 · Grant/award (A): 139,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Townson Sharon — Chief Scientific Officer | Grant/award (A): 35,000 · Sale (S): 3,155 @ $15.17 · Grant/award (A): 158,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Hughes Eric A — Director | Grant/award (A): 30,700 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Blackwell Kimberly — Director | Grant/award (A): 30,700 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Skvarka Jan — Director | Grant/award (A): 30,700 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Siu Christine — Director | Grant/award (A): 30,700 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Manning Anthony M. — Director | Grant/award (A): 30,700 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Behbahani Ali — Director, 10% owner | Grant/award (A): 30,700 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | SCHIFF ANDREW N — Director | Grant/award (A): 30,700 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Dunn Edmund — Principal Accounting Officer | Sale (S): 2,062 @ $4.45 | EDGAR |
| 2025-03-25 | 4 | Leo Chandra P. — Director | Purchase (P): 10,000 @ $5.84 | EDGAR |
| 2025-01-06 | 4 | Townson Sharon — Chief Scientific Officer | Grant/award (A): 36,000 · Grant/award (A): 161,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Monte Rosa Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-01 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-01-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GLUE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →